Dr. Mohammad AlNajjar started his subspecialized bone marrow stem cell transplant and cellular therapy clinical fellowship in 2022. He received all of his medical education, including his training in pediatric hematology and oncology, in Canada prior to joining Texas Children's.
His dedication to cancer research started over a decade ago prior to medical school. He participated in translational clinical work focusing on cancer-initiating stem cells. Dr. AlNajjar's commitment and dedication to patient's care in oncology never faded away. He is currently finishing up additional training in bone marrow transplant and cellular therapy to be able to better care for patients with both malignant (e.g., blood cancer or leukemia), as well as non-malignant disease requiring stem cell transplantation.
His specific research interests include: the diagnosis and management of bone marrow transplant complications, including but not limited to, immune dysregulation complications post bone marrow transplant, and transplant-associated thrombotic microangiopathy (TA-TMA), which is a complication whereby the endothelial cell lining of various organ systems sustain damages following bone marrow transplant.